BioNTech SE (BNTX)
| Market Cap | 24.67B -4.6% |
| Revenue (ttm) | 3.23B +2.1% |
| Net Income | -1.44B |
| EPS | -5.89 |
| Shares Out | 252.88M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,390,437 |
| Open | 94.49 |
| Previous Close | 93.92 |
| Day's Range | 94.49 - 98.81 |
| 52-Week Range | 79.52 - 124.00 |
| Beta | 1.32 |
| Analysts | Buy |
| Price Target | 122.01 (+25.08%) |
| Earnings Date | Aug 4, 2026 |
About BNTX
BioNTech SE, together with its subsidiaries, engages in the development and commercialization of immunotherapies in Germany. The company offers BNT162, an mRNA vaccine for the treatment of SARS-CoV-2 virus. It also develops oncology drugs under Phase III clinical trial, including Gotistobart for metastatic non-small cell lung cancer, Pumitamig for small cell lung cancer and advanced/metastatic triple-negative breast cancer, and Trastuzumab pamirtecan for metastatic breast cancer and epirubicin and cyclophosphamide; and drugs under Phase 2/3 cli... [Read more]
Financial Performance
In 2025, BioNTech SE's revenue was 2.87 billion, an increase of 4.32% compared to the previous year's 2.75 billion. Losses were -1.14 billion, 70.8% more than in 2024.
Financial numbers in EUR Financial StatementsAnalyst Summary
According to 20 analysts, the average rating for BNTX stock is "Buy." The 12-month stock price target is $122.01, which is an increase of 25.08% from the latest price.
News
BioNTech held buyer talks over four German sites set to close, Handelsblatt reports
BioNTech has held confidential talks with potential buyers about the German sites that the COVID‑19 vaccine maker plans to close, which has now grown to four locations, the Handelsblatt newspaper r...
Moderna interested in Germany production, sees opportunity in BioNTech closures, says CEO
U.S. pharmaceutical company Moderna is interested in investing in production facilities in Germany, with an eye on plants that its German rival BioNTech plans to close, CEO Stephane Bancel tol...
Global Data for BioNTech and Bristol Myers Squibb's PD-L1xVEGF-A Bispecific Pumitamig Shows Encouraging Efficacy in Patients with Non-Small Cell Lung Cancer in ROSETTA Lung-02 Trial
First investigational PD-(L)1xVEGF bispecific immunomodulator to present global data showing encouraging efficacy in combination with chemotherapy in first-line non-small cell lung cancer across PD-L1...
This Biotech's Cancer Portfolio Could End Its Rough Patch
The drugmaker is looking to its oncology pipeline to drive its next leg of growth.
BioNTech to Showcase Progress Across Late-Stage Oncology Pipeline at the 2026 ASCO Annual Meeting
Pumitamig data from the ongoing Phase 2/3 ROSETTA Lung-02 trial in first-line non-small cell lung cancer mark the third global data set to consistently show encouraging anti-tumor activity for pumitam...
BioNTech SE Shareholders Approve All Agenda Items at the Annual General Meeting 2026
MAINZ, Germany, May 15, 2026 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) held its Annual General Meeting (“AGM”) today. A total of 92 per cent of the share capital was ...
BioNTech SE Transcript: AGM 2026
The AGM highlighted strong financials, strategic focus on oncology, and major leadership transitions. All management proposals, including board expansion and capital measures, were approved by large majorities. Manufacturing consolidation and a $1B share buyback were key initiatives.
BioNTech Announces New ADS Repurchase Program
MAINZ, Germany, May 7, 2026 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) today announced that it has authorized a new share repurchase program (the “Program”), under whi...
Germany says vaccine supply secure despite BioNTech production loss
A German government spokesperson said on Wednesday that the loss of BioNTech vaccine production in the country can be offset by other companies.
BioNTech SE Earnings Call Transcript: Q1 2026
Q1 2026 revenues declined year-over-year due to lower COVID-19 vaccine demand, while oncology pipeline progress continued with strong late-stage data for pumitamig, gotistobart, and T-Pam. Full-year guidance was reaffirmed, and a €1B share buyback and manufacturing consolidation were announced.
BioNTech SE Earnings release: Q1 2026
BioNTech SE released its Q1 2026 earnings on May 5, 2026, summarizing the period's financial results.
BioNTech SE Slides: Q1 2026
BioNTech SE has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 5, 2026.
BioNTech to Close Sites, Cut Quarter of Workforce in Savings Push
The company said it would exit operations at some manufacturing plants in Germany and Singapore, as well as sites it acquired as part of its CureVac takeover.
BioNTech to close sites in Germany, Singapore affecting 1,860 staff
Germany's BioNTech said on Tuesday it would close sites affecting up to 1,860 jobs and buy back up to $1 billion worth of its shares, following the announcement of two co-founders quitting the COVID...
BioNTech Announces First Quarter 2026 Financial Results and Corporate Update
BioNTech SE (Nasdaq: BNTX) today reported financial results for the three months ended March 31, 2026 and provided an update on its corporate progress.
Two experimental drugs showed striking early results against pancreatic cancer
Results from two early-stage trials offer new hope for a cancer that kills around one in eight patients within five years.
BioNTech to Report First Quarter 2026 Financial Results and Corporate Update on May 5, 2026
MAINZ, Germany, April 21, 2026 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will announce its financial results for the first quarter 2026 on Tuesday, May 5, 2026. Addit...
BioNTech and DualityBio's Antibody-Drug Conjugate Trastuzumab Pamirtecan Demonstrated Clinically Meaningful Efficacy in Patients with HER2-Expressing, Recurrent Endometrial Cancer
BioNTech today announced positive results from the primary analysis of a Phase 2 cohort evaluating trastuzumab pamirtecan in HER2+ endometrial cancer.
Exclusive: Pfizer, BioNTech halt US COVID vaccine study after recruitment struggles
Vaccine makers Pfizer and BioNTech have halted recruitment for a large U.S. trial of their updated COVID-19 vaccine in healthy adults aged 50 to 64, saying enrollment in the trials had been too low ...
BioNTech Clinical Data at ELCC 2026 Highlight Potential of Differentiated Late-Stage Portfolio in Lung Cancer
MAINZ, Germany, March 24, 2026 – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will present data from its diversified portfolio in the field of lung cancer at the European Lung Cancer Congre...
BioNTech SE Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
SAN DIEGO, March 10, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of investors of BioNTech SE (NASDAQ: BNTX). The investigation focuses on BioNTech's execu...
One simple reason why BioNTech stock is a raging buy on today's crash
BioNTech (NASDAQ: BNTX) swung to a Q4 loss and guided for “lower-than-expected” full-year revenue on Tuesday. But the stock crashed more than 20%, mostly because its cofounders, Ugur Sahin (CEO) and O...
BioNTech SE Earnings Call Transcript: Q4 2025
Strong oncology pipeline progress and exceeded 2025 revenue guidance, ending with EUR 17.2B in cash. 2026 outlook anticipates lower COVID-19 vaccine revenues, increased investment in late-stage oncology, and key data readouts.
BioNTech SE Annual report: Q4 2025
BioNTech SE has published its Q4 2025 annual report on March 10, 2026.
BioNTech SE Earnings release: Q4 2025
BioNTech SE released its Q4 2025 earnings on March 10, 2026, summarizing the period's financial results.